

500,200

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
17 July 2003 (17.07.2003)

PCT

(10) International Publication Number  
**WO 03/057249 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 39/395**,  
31/436, A61P 37/08, 11/06

Novartis Horsham Research Centre, Wimbleshurst Road,  
Horsham, West Sussex RH12 5AB (CH).

(21) International Application Number: PCT/EP03/00154

(74) Agents: **GROS, Florent** et al.; Novartis AG, Corporate  
Intellectual Property, Patent & Trademark Department,  
CH-4002 Basel (CH).

(22) International Filing Date: 9 January 2003 (09.01.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0200429.9 9 January 2002 (09.01.2002) GB

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,  
LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH,  
PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT,  
UA, US, UZ, VC, VN, YU, ZA, ZW.

(71) Applicant (*for all designated States except AT, US*): **NO-  
VARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel  
(CH).

(84) Designated States (*regional*): Eurasian patent (AM, AZ,  
BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE,  
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU,  
IE, IT, LU, MC, NL, PT, SE, SI, SK, TR).

(71) Applicant (*for AT only*): **NOVARTIS PHARMA GMBH**  
[AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

**Published:**

- with international search report
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **OWEN, Charles,  
Edward** [GB/GB]; Novartis Horsham Research Centre,  
Wimbleshurst Road, Horsham, West Sussex RH12 5AB  
(GB). **FOX, Howard** [US/US]; Novartis Horsham Re-  
search Centre, Wimbleshurst Road, Horsham, West Sussex  
RH12 5AB (US). **WALKER, Christoph** [GB/GB];

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: COMBINATION TREATMENTS FOR ALLERGIC DISEASE COMPRISING ADMINISTERING AN ANTI-IGE AN-  
TIBODY AND ANTIALLERGIC COMPOUND

(57) Abstract: Pharmaceutical composition comprising an anti-IgE antibody and at least one further antiallergic compound selected from the group consisting of anti-inflammatory agents, leukotriene modifiers, bronchodilators, antihistamines, interleukin antagonists, mast cell inhibitors, and immunotherapeutical agents, such as 33-epichloro, 33-desoxyzascomycin (pimecrolimus), in which the active ingredients are present in free form or in the form of a pharmaceutically acceptable salt and optionally at least one pharmaceutically acceptable carrier; for simultaneous, separate or sequential use.

WO 03/057249 A1